Ranbaxy Laboratories Limited (Ranbaxy) has announced that The District Court of The Hague has handed down a decision in Ranbaxy's case against (Pfizer) Warner-Lambert over the cholesterol-lowering dru
Court cases regarding patent infringement effectively slow generics in coming to market, however US lawmakers and FDA continue to make it easier for generic drugs to gain approval (Cutting Edge In
Researchers at Virginia Commonwealth University Medical Center have developed and patented a new, noninvasive means of measuring blood pressure inside the heart. The measurement to determine centr
SpectraScience has announced that it has filed for a new patent with the United States Patent and Trademark Office. The application is titled "System and Method for Non-Endoscopic Optica
NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparti
Applied Digital Solutions, though its subsidiary VeriChip Corporation has announced today that the U.S. Patent and Trademark Office has granted VeriChip Corp. a patent for its portable RFID asset
MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.: By granting MedImmune's appeal, the U.S. Supr
Ryogen LLC announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation, whereby Invitrogen has licensed from Ryogen the patent directed to the clinic
CogState has announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests
Acusphere, Inc. announced today the issuance of U.S. Patent No. 7,160,557 B2, entitled "Matrices Formed of Polymer and Hydrophobic Compounds for Use in Drug Delivery." The patent covers the s
Prior to the introduction of the Vapotherm high flow oxygen therapy system, providing medical gas via a nasal cannula was limited to lower flow rates. The Vapotherm system is able to substantially increase nasal cannula flow in a range such as 1 - 40 LPM.
"As our knowledge increases and we continue to innovate, we are significantly expanding our intellectual property," said David Lain, VP of Clinical Development.
The first of the Company's recent patent application publications is for the Vapotherm Patient Delivery Tube. This delivery tube enables maintenance of breathing gas temperature and humidification, while minimizing rainout. In addition, this new technology eliminates the need for heated wires within a patient breathing circuit. The second technology that is the subject of a patent application publication is the Vapotherm Low Flow Vapor Transfer Cartridge, used extensively in the neonatal and infant population. This specialized cartridge allows for optimal conditioning of gases delivered at lower flows such as 1-8 LPM.
The final announced patent application publication relates to an invention of Dr. Owen Bamford, involving the reduction of work of breathing. "This is an important invention of Dr. Bamford," said Dr. Lain. "Until the introduction of the Vapotherm technology, the concept that there is a reduction in work of breathing created when using high flow nasal cannula system, was unknown. Dr. Bamford has demonstrated that the work of breathing using high flow therapy via the Vapotherm system decreases as much as three fold. The clinical utility of the Vapotherm high flow nasal cannula to reduce work of breathing will be beneficial to patients experiencing respiratory compromise."
http://www.vtherm.com